Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

导出原文传递

翻译打印收藏纠错

作者： Bug, G. ^[1] ; Burchert, A. ^[2] ; Wagner, E-M ^[3] ; Kroeger, N. ^[4] ; Berg, T. ^[5] ; Gueller, S. ^[6] ; Metzelder, S. K. ^[7] ; Wolf, A. ; Huenecke, S. ; Bader, P. ; Schetelig, J. ; Serve, H. ; Ottmann, O. G.

作者单位： Univ Hosp, Dept Med 2, Frankfurt, Germany ^[1] Univ Med Ctr, Dept Med 3, Mainz, Germany ^[2] Univ Hosp, Dept Children & Adolescents, Frankfurt, Germany ^[3] Univ Klinikum, Med Klin & Poliklin 1, Dresden, Germany ^[4] Univ Hosp, Dept Stem Cell Transplantat, Hamburg, Germany ^[5] Cardiff Univ, Div Canc & Genet, Dept Haematol, Cardiff, S Glam, Wales ^[6] Univ Klinikum, Dept Hematol Oncol & Immunol, Marburg, Germany ^[7]

发布时间 2018-04-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Leukemia

2017年31卷11期

2523-2525页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Leukemia

相似文献

Leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Leukemia

相似文献

Leukemia

相关期刊

检索历史清除